Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Adjuvant T-DM1 bij stadium I HER2-positieve borstkanker: resultaten na 5 jaar
nov 2024 | Borstkanker